In response to my claim that public understanding of fiscal policy is dominated by fallacious analogies between a national government and a household, MF asks for an explanation “Why is that analogy deceptive or misleading?”
The start of a new year causes many people to vow to change, make resolutions or try something new — after their hangover wears off anyway. For investors, it can be a good time to review their portfolios, investment goals and strategies: Is your investment plan working? Is your advisor earning his or her keep? Is your portfolio diversified and balanced?
By Chris Katje: Last week, shares of TearLab Corporation (TEAR) jumped 12.6%. The move came from increased volume and a buy recommendation from stock picker and CNBC host Jim Cramer. The company is still underfollowed and undervalued, but that is about to change.
Today’s big stock market winner is Sarepta Therapeutics (SRPT), a small biotech company developing Eteplirsen, a novel therapy for Duchenne Muscular Dystrophy. Shares are rocketing higher by a stunning 175% today, from $15 to $41 each, on news that a phase 2 study showed promising results compared with placebo.
Yes, the federal government does a lot of stupid things. And yes, it's easy to see why Wall Street firms are bailing out of the Troubled Asset Relief Program: to avoid having to deal with the government's ever-changing rules and with publicity-hungry congressmen. (Is there any other kind?) But that doesn't excuse the way that Wall Street is engaged in selective memory now that the government has shelled out trillions of taxpayer dollars to keep the Street alive.